## **Catherine Legrand**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2615381/publications.pdf Version: 2024-02-01



CATHEDINE LECDAND

#	Article	IF	CITATIONS
1	Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine, 2019, 37, 2004-2015.	3.8	42
2	Variable selection in a flexible parametric mixture cure model with interval ensored data. Statistics in Medicine, 2016, 35, 1210-1225.	1.6	40
3	Selective Use of Sequential Digital Dermoscopy Imaging Allows a Cost Reduction in the Melanoma Detection Process: A Belgian Study of Patients with a Single or a Small Number of Atypical Nevi. PLoS ONE, 2014, 9, e109339.	2.5	25
4	Melanoma burden by melanoma stage: Assessment through a disease transition model. European Journal of Cancer, 2016, 53, 33-41.	2.8	20
5	The Single-Index/Cox Mixture Cure Model. Biometrics, 2019, 75, 452-462.	1.4	16
6	Inference in a survival cure model with mismeasured covariates using a simulation-extrapolation approach. Biometrika, 2017, 104, asw054.	2.4	14
7	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. Contemporary Clinical Trials, 2020, 99, 106189.	1.8	14
8	DNA alterationâ€based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in highâ€risk group. Cancer Medicine, 2019, 8, 3036-3046.	2.8	13
9	Diagnostic checks in mixture cure models with interval-censoring. Statistical Methods in Medical Research, 2018, 27, 2114-2131.	1.5	11
10	Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European Journal of Cancer, 2016, 67, 38-45.	2.8	10
11	Flexible Parametric Approach to Classical Measurement Error Variance Estimation Without Auxiliary Data. Biometrics, 2019, 75, 297-307.	1.4	10
12	Robustness of estimation methods in a survival cure model with mismeasured covariates. Computational Statistics and Data Analysis, 2017, 113, 3-18.	1.2	9
13	Evaluating case management as a complex intervention: Lessons for the future. PLoS ONE, 2019, 14, e0224286.	2.5	7
14	Joint longitudinal and time-to-event cure models for the assessment of being cured. Statistical Methods in Medical Research, 2020, 29, 1256-1270.	1.5	6
15	A note on tests for relevant differences with extremely large sample sizes. Biometrical Journal, 2019, 61, 162-165.	1.0	4
16	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. Biometrical Journal, 2021, 63, 272-288.	1.0	4
17	Likelihood-Based Inference for Semi-Competing Risks. Communications in Statistics Part B: Simulation and Computation, 2014, 43, 1112-1132.	1.2	2
18	Testing for decreasing heterogeneity in a new time-varying frailty model. Test, 2016, 25, 591-606.	1.1	2

2

#	ARTICLE	IF	CITATIONS
19	Waiting period from diagnosis for mortgage insurance issued to cancer survivors. European Actuarial Journal, 2020, 11, 135.	1.1	1
20	Evaluating case management as a complex intervention: Lessons for the future. , 2019, 14, e0224286.		0
21	Evaluating case management as a complex intervention: Lessons for the future. , 2019, 14, e0224286.		0
22	Evaluating case management as a complex intervention: Lessons for the future. , 2019, 14, e0224286.		0
23	Evaluating case management as a complex intervention: Lessons for the future. , 2019, 14, e0224286.		0